Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jan 13;11(1):12.
doi: 10.1186/s13256-016-1175-1.

Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports

Joana Oliveira  1   2 , Eva Lau  3   4 , Davide Carvalho  3   4 , Paula Freitas  3   4
Affiliations
Case Reports

Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports

Joana Oliveira et al. J Med Case Rep. .

Abstract

Background: Lipodystrophic syndromes are uncommon medical conditions which are normally associated with metabolic disorders, such as diabetes mellitus, dyslipidemia, and fatty liver disease. These complications are generally difficult to treat, particularly diabetes, due to severe insulin resistance. We present two case reports of successful treatment of diabetes with glucagon-like peptide-1 analogues in patients with clinical features of lipodystrophic syndromes.

Case presentation: Two white women aged 49 and 60 years manifested marked central body fat deposition with severe lipoatrophy of their limbs and buttocks and pronounced acanthosis nigricans. They had hypertension, dyslipidemia, fatty liver disease, and poorly controlled diabetes (glycated hemoglobin 8.3% and 10.2%, respectively) despite the use of three classes of oral antidiabetic drugs taken in combination in the first case, and high doses of insulin in the second case. Four months after the addition of glucagon-like peptide-1 analogue to their previous treatment they both showed a pronounced improvement in metabolic control (glycated hemoglobin 5.6% and 6.2%, respectively). In the first case, a weight loss of nearly 30 kg was recorded.

Conclusions: We intend to demonstrate that glucagon-like peptide-1 analogues could be a valuable tool for patients with lipodystrophic disorders, probably by improving body fat distribution, with favorable results in insulin-sensitivity and glycemic control.

Keywords: Diabetes mellitus; GLP-1 analogues; Lipodystrophy.

PubMed Disclaimer

References

    1. Fardet L, Vigourox C, Capeau J. Syndromes lipodystrophiques. Rev Med Interne. 2013;34(10):614–22. doi: 10.1016/j.revmed.2012.11.008. - DOI - PubMed
    1. Vatier C, Bidault G, Briand N, Guénantin AC, Teyssières L, Lascols O, Capeau J, Vigouroux C. What the Genetics of Lipodystrophy Can Teach Us About Insulin Resistance and Diabetes. Curr Diab Rep. 2013;13(6):757–67. doi: 10.1007/s11892-013-0431-7. - DOI - PubMed
    1. Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J Hum Genet. 2014;59(1):16–23. doi: 10.1038/jhg.2013.107. - DOI - PubMed
    1. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, Reitman ML. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest. 2000;105(3):271–8. doi: 10.1172/JCI7901. - DOI - PMC - PubMed
    1. Reitman ML, Arioglu E, Gavrilova O, Taylor SI. Lipoatrophy revisited. Trends Endocrinol Metab. 2000;11(10):410–6. doi: 10.1016/S1043-2760(00)00309-X. - DOI - PubMed

Publication types

MeSH terms

Substances